Rituximab-based treatment, HCV replication, and hepatic flares

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Sagnelli, Evangelista ^a,b   Pisaturo, Mariantonietta ^a,b   Sagnelli, Caterina ^a   Coppola, Nicola ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b Division of Infectious Diseases   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; PIRARUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; R CHOP PROTOCOL; R-CHOP PROTOCOL;

ASCITES; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CRYOGLOBULINEMIA; CYTOMEGALOVIRUS; DISEASE EXACERBATION; DRUG ANTAGONISM; DRUG WITHDRAWAL; ECHO VIRUS; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN PARVOVIRUS B19; IMMUNITY; LARGE CELL LYMPHOMA; LIVER CELL; LIVER DISEASE; LIVER FAILURE; LIVER TOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; VARICELLA ZOSTER VIRUS; VASCULITIS; VIRUS REACTIVATION; VIRUS REPLICATION; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HEMATOLOGIC DISEASE; PHYSIOLOGY; RECURRENT DISEASE; VIROLOGY; VIRUS ACTIVATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMATOLOGIC NEOPLASMS; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER FAILURE; PREDNISONE; RECURRENCE; VINCRISTINE; VIRUS ACTIVATION; VIRUS REPLICATION;

EID: 84866134351     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/945950     Document Type: Review

References (49)

1. El Hoofnagle J., Tralka T. S., Introduction: The National Institutes of Health Consensus Development Conference: management of hepatitis C virus. Hepatology 1997 26 3, supplement 1S 2S 2-s2.0-0030924537
2. Zignego A. L., Macchia D., Monti M., Thiers V., Mazzetti M., Foschi M., Maggi E., Romagnani S., Gentilini P., Brechot C., Infection of peripheral mononuclear blood cells by hepatitis C virus. Journal of Hepatology 1992 15 3 382 386 2-s2.0-0026761707 10.1016/0168-8278(92)90073-X
3. Zignego A. L., Giannini C., Monti M., Gragnani L., Hepatitis C virus lymphotropism: lessons from a decade of studies. Digestive and Liver Disease 2007 39 1 S38 S45 2-s2.0-34948827431 10.1016/S1590-8658(07)80009-0 (Pubitemid 47528193)
4. Ferri C., Caracciolo F., Zignego A. L., La Civita L., Monti M., Longombardo G., Lombardini F., Greco F., Capochiani E., Mazzoni A., Mazzaro C., Pasero G., Hepatitis C virus infection in patients with non-Hodgkin's lymphoma. British Journal of Haematology 1994 88 2 392 394 2-s2.0-0027944012 (Pubitemid 24318191)
5. Silvestri F., Pipan C., Barillari G., Zaja F., Fanin R., Infanti L., Russo D., Falasca E., Botta G. A., Baccarani M., Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996 87 10 4296 4301 2-s2.0-9344248984 (Pubitemid 26152271)
6. Zuckerman E., Zuckerman T., Levine A. M., Douer D., Gutekunst K., Mizokami M., Qian D. G., Velankar M., Nathwani B. N., Fong T. L., Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Annals of Internal Medicine 1997 127 6 423 428 2-s2.0-0030852545 (Pubitemid 27400904)
7. Misiani R., Bellavita P., Fenili D., Borelli G., Marchesi D., Massazza M., Vendramin G., Comotti B., Tanzi E., Scudeller G., Zanetti A., Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Annals of Internal Medicine 1992 117 7 573 577 2-s2.0-0026674225
8. Agnello V., Chung R. T., Kaplan L. M., A role for hepatitis C virus infection in Type II cryoglobulinemia. New England Journal of Medicine 1992 327 21 1490 1495 2-s2.0-0026439201
9. Marcellin P., Descamps V., Martinot-Peignoux M., Larzul D., Xu L., Boyer N., Pham B. N., Crickx B., Guillevin L., Belaich S., Erlinger S., Benhamou J. P., Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology 1993 104 1 272 277 2-s2.0-0027500123 (Pubitemid 23040033)
10. Haddad J., Deny P., Munz-Gotheil C., Ambrosini J. C., Trinchet J. C., Pateron D., Mal F., Callard P., Beaugrand M., Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease. The Lancet 1992 339 8789 321 323 2-s2.0-0026609845 10.1016/0140-6736(92)91645-O
11. Pawlotsky J. M., Roudot-Thoraval F., Simmonds P., Mellor J., Yahia M. B., Andre C., Voisin M. C., Intrator L., Zafrani E. S., Duval J., Dhumeaux D., Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Annals of Internal Medicine 1995 122 3 169 173 2-s2.0-0028873811
12. Gumber S. C., Chopra S., Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Annals of Internal Medicine 1995 123 8 615 620 2-s2.0-0028876341
13. Hadziyannis S. J., The spectrum of extrahepatic manifestations in hepatitis C virus infection. Journal of Viral Hepatitis 1997 4 1 9 28 2-s2.0-0030635787 (Pubitemid 127733514)
14. Clifford B. D., Donahue D., Smith L., Cable E., Luttig B., Manns M., Bonkovsky H. L., High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995 21 3 613 619 2-s2.0-0028900670
15. Prieto J., Yuste J. R., Beloqui O., Civeira M. P., Riezu J. I., Aguirre B., Sangro B., Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome. Hepatology 1996 23 2 199 204 2-s2.0-0030059648 10.1053/jhep.1996.v23.pm0008591841 (Pubitemid 26045934)
16. Stashenko P., Nadler L. M., Hardy R., Schlossman S. F., Characterization of a human B lymphocyte-specific antigen. Journal of Immunology 1980 125 4 1678 1685 2-s2.0-0018949401 (Pubitemid 10018582)
17. Cheson B. D., CHOP plus rituximabbalancing facts and opinion. New England Journal of Medicine 2002 346 4 280 282 2-s2.0-0037165271 10.1056/ NEJM200201243460411 (Pubitemid 34438869)
18. Reff M. E., Carner K., Chambers K. S., Chinn P. C., Leonard J. E., Raab R., Newman R. A., Hanna N., Anderson D. R., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994 83 2 435 445 2-s2.0-0028057250 (Pubitemid 24030569)
19. McLaughlin P., Grillo-López A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 1998 16 8 2825 2833 2-s2.0-0345337254 (Pubitemid 28363048)
20. Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Burmester G. R., Sieper J., Emery P., Keystone E. C., Schiff M. H., Mease P., Van Riel P. L. C. M., Fleischmann R., Weisman M. H., Weinblatt M. E., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Annals of the Rheumatic Diseases 2007 66 supplement 3 iii2 iii22 2-s2.0-35649016260 10.1136/ard.2007.081430 (Pubitemid 350032626)
21. Cacoub P., Delluc A., Saadoun D., Landau D. A., Sene D., Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemia vasculitis: where do we stand? Annals of the Rheumatic Diseases 2008 67 3 283 287 2-s2.0-39549109812 10.1136/ard.2006.065565 (Pubitemid 351281259)
22. Saadoun D., Rosenzwajg M., Landau D., Piette J. C., Klatzmann D., Cacoub P., Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008 111 11 5334 5341 2-s2.0-45949090087 10.1182/blood-2007-11-122713
23. Aksoy S., Harputluoglu H., Kilickap S., Dede D. S., Dizdar O., Altundag K., Barista I., Rituximab-related viral infections in lymphoma patients. Leukemia and Lymphoma 2007 48 7 1307 1312 2-s2.0-34447566087 10.1080/10428190701411441 (Pubitemid 47079357)
24. Yeo W., Johnson P. J., Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006 43 2 209 220 2-s2.0-33644545429 10.1002/hep.21051
25. Loomba R., Rowley A., Wesley R., Liang T. J., Hoofnagle J. H., Pucino F., Csako G., Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Annals of Internal Medicine 2008 148 7 519 528 2-s2.0-42249113025 (Pubitemid 351665421)
26. Hsu C., Hsiung C. A., Su I. J., Hwang W. S., Wang M. C., Lin S. F., Lin T. H., Hsiao H. H., Young J. H., Chang M. C., Liao Y. M., Li C. C., Wu H. B., Tien H. F., Chao T. Y., Liu T. W., Cheng A. L., Chen P. J., A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial. Hepatology 2008 47 3 844 853 2-s2.0-40949125163 10.1002/hep.22106 (Pubitemid 351449676)
27. Palmore T. N., Shah N. L., Loomba R., Borg B. B., Lopatin U., Feld J. J., Khokhar F., Lutchman G., Kleiner D. E., Young N. S., Childs R., Barrett A. J., Liang T. J., Hoofnagle J. H., Heller T., Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression. Clinical Gastroenterology and Hepatology 2009 7 10 1130 1137 2-s2.0-70349528167 10.1016/j.cgh.2009.06.027
28. Fukushima N., Mizuta T., Tanaka M., Yokoo M., Ide M., Hisatomi T., Kuwahara N., Tomimasu R., Tsuneyoshi N., Funai N., Sueoka E., Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Annals of Oncology 2009 20 12 2013 2017 2-s2.0-70350066135 10.1093/annonc/mdp230
29. Yeo W., Chan T. C., Leung N. W. Y., Lam W. Y., Mo F. K. F., Miu T. C., Chan H. L. Y., Hui E. P., Lei K. I. K., Mok T. S. K., Chan P. K. S., Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. Journal of Clinical Oncology 2009 27 4 605 611 2-s2.0-59149085061 10.1200/JCO.2008.18.0182
30. Pei S. N., Chen C. H., Lee C. M., Wang M. C., Ma M. C., Hu T. H., Kuo C. Y., Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Annals of Hematology 2010 89 3 255 262 2-s2.0-77949330147 10.1007/s00277-009-0806-7
31. Koo Y. X., Tan D. S. W., Tan I. B., Tao M., Chow W. C., Lim S. T., Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer 2010 116 1 115 121 2-s2.0-74549162133 10.1002/cncr.24742
32. Marzano A., Angelucci E., Andreone P., Brunetto M., Bruno R., Burra P., Caraceni P., Daniele B., Di Marco V., Fabrizi F., Fagiuoli S., Grossi P., Lampertico P., Meliconi R., Mangia A., Puoti M., Raimondo G., Smedile A., Prophylaxis and treatment of hepatitis B in immunocompromised patients. Digestive and Liver Disease 2007 39 5 397 408 2-s2.0-34047151232 10.1016/j.dld.2006.12.017 (Pubitemid 46508732)
33. Coppola N., Tonziello G., Pisaturo M., Messina V., Guastafierro S., Fiore M., Iodice V., Sagnelli C., Stanzione M., Capoluongo N., Pasquale G., Sagnelli E., Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. Journal of Medical Virology 2011 83 11 1909 1916 2-s2.0-80052784063 10.1002/jmv.22199
34. Aksoy S., Abali H., Kilickap S., Erman M., Kars A., Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient. Clinical and Laboratory Haematology 2006 28 3 211 214 2-s2.0-33646736312 10.1111/j.1365-2257.2006.00779.x
35. Nooka A., Shenoy P. J., Sinha R., Lonial S., Flowers C. R., Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clinical Lymphoma, Myeloma and Leukemia 2011 11 5 379 384 2-s2.0-83455197924 10.1016/j.clml.2011.04.005
36. Ennishi D., Maeda Y., Niitsu N., Kojima M., Izutsu K., Takizawa J., Kusumoto S., Okamoto M., Yokoyama M., Takamatsu Y., Sunami K., Miyata A., Murayama K., Sakai A., Matsumoto M., Shinagawa K., Takaki A., Matsuo K., Kinoshita T., Tanimoto M., Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010 116 24 5119 5125 2-s2.0-78650074442 10.1182/blood-2010-06-289231
37. Tsutsumi Y., Ichiki K., Shiratori S., Kawamura T., Tanaka J., Asaka M., Imamura M., Masauzi N., Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. International Journal of Laboratory Hematology 2009 31 4 468 470 2-s2.0-67651098723 10.1111/j.1751-553X.2008.01034.x
38. Pitini V., Sturniolo G., Arrigo C., Leonardi S., Pino S., Altavilla G., HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy: correspondence. British Journal of Haematology 2010 150 1 116 118 2-s2.0-77953531899 10.1111/j.1365-2141.2010.08154.x
39. Marignani M., Mangone M., Cox M. C., Angeletti S., Veggia B., Ferrari A., di Fonzo M., Begini P., Gigante E., Laverde G., Aloe-Spiriti A., Monarca B., Fave G. D., HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Digestive and Liver Disease 2011 43 2 139 142 2-s2.0-78651445038 10.1016/j.dld.2010.05.010
40. Coppola N., Pisaturo M., Guastafierro S., Tonziello G., Sica A., Iodice V., Sagnelli C., Ferrara M. G., Sagnelli E., Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Digestive and Liver Disease 2012 44 1 49 54 2-s2.0-83855160892 10.1016/j.dld.2011.07.016
41. Hsieh C. Y., Huang H. H., Lin C. Y., Lo W. C., Liao Y. M., Bai L. Y., Chiu C. F., Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma. Journal of Clinical Oncology 2008 26 15 2584 2586 2-s2.0-45149088491 10.1200/JCO.2007.15.4807
42. Lake-Bakaar G., Dustin L., McKeating J., Newton K., Freeman V., Frost S. D. W., Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 2007 109 2 845 846 2-s2.0-33846243704 (Pubitemid 46105993)
43. Arcaini L., Merli M., Passamonti F., Bruno R., Brusamolino E., Sacchi P., Rattotti S., Orlandi E., Rumi E., Ferretti V., Rizzi S., Meli E., Pascutto C., Paulli M., Lazzarino M., Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. American Journal of Hematology 2010 85 1 46 50 2-s2.0-74049084986 10.1002/ajh.21564
44. Petrarca A., Rigacci L., Caini P., Colagrande S., Romagnoli P., Vizzutti F., Arena U., Giannini C., Monti M., Montalto P., Matucci-Cerinic M., Bosi A., Laffi G., Zignego A. L., Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010 116 3 335 342 2-s2.0-77955915180 10.1182/blood-2009-11-253948
45. Silverman G. J., Weisman S., Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis and Rheumatism 2003 48 6 1484 1492 2-s2.0-0037638841 10.1002/art.10947 (Pubitemid 36682354)
46. Ciesek S., Steinmann E., Iken M., Ott M., Helfritz F. A., Wappler I., Manns M. P., Wedemeyer H., Pietschmann T., Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus. Gastroenterology 2010 138 5 1875 1884 2-s2.0-77951863795 10.1053/j.gastro.2010.02.004
47. Zeisel M. B., Fofana I., Fafi-Kremer S., Baumert T. F., Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. Journal of Hepatology 2011 54 3 566 576 2-s2.0-79951669627 10.1016/j.jhep.2010.10.014
48. Visco C., Arcaini L., Brusamolino E., Burcheri S., Ambrosetti A., Merli M., Bonoldi E., Chilosi M., Viglio A., Lazzarino M., Pizzolo G., Rodeghiero F., Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Annals of Oncology 2006 17 9 1434 1440 2-s2.0-33748744162 10.1093/annonc/mdl131 (Pubitemid 44400383)
49. Coppola N., Pisaturo M., Guastafierro S., Tonziello G., Sica A., Sagnelli C., Ferrara M. G., Sagnelli E., Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases. Hepatology 2011 54 4 1487 1489 2-s2.0-80053327099 10.1002/hep.24436